CEO David Hallal shared with CNBC how ElevateBio is disrupting the industry by offering partners an integrated tech stack with end-to-end manufacturing through its genetic medicine foundry model. Watch his full interview at https://lnkd.in/eACRdDps.
ElevateBio
Biotechnology Research
Waltham, Massachusetts 33,537 followers
A cell and gene therapy company accelerating access to technologies and expertise to change the future of medicine.
About us
ElevateBio is a technology-driven company built to power transformative genetic medicines today and for many decades to come. The Company commercializes its enabling technologies, manufacturing capabilities, and industry-leading expertise through partnerships to accelerate development across a breadth of therapeutic approaches and modalities. The ElevateBio ecosystem combines multiple R&D technology platforms – including Life Edit, a next-generation, full-spectrum gene editing platform; comprehensive cell engineering technologies; and an expanded viral and non-viral therapeutic delivery platform – with BaseCamp®, its end-to-end genetic medicine cGMP manufacturing and process development business, to accelerate the discovery and development of advanced therapeutics. ElevateBio aims to be the dominant engine inside the world’s greatest scientific advancements harnessing human cells and genes to alter disease.
- Website
-
https://www.elevate.bio/
External link for ElevateBio
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Waltham, Massachusetts
- Type
- Privately Held
- Specialties
- cell therapy, gene therapy, and cell and gene therapy
Locations
-
Primary
200 Smith St
Waltham, Massachusetts 02451, US
Employees at ElevateBio
Updates
-
Hear what Esther Radovsky Driscoll, Associate Director, Contracts Administration, has to say about working with innovators at ElevateBio:
-
-
To our hardworking team, our partners, and our network - Happy Labor Day! #LaborDay #ElevateBio
-
-
We offer a range of delivery capabilities, including viral and non-viral delivery platforms. Our novel non-viral lipid nanoparticle (LNP) platform has both liver targeting and de-targeting potential unlocking new possibilities for addressing a wide range of diseases and disorders. Learn more: https://lnkd.in/e8PRHJnj.
-
-
We’re proud to partner with Affini-T Therapeutics as they leverage ElevateBio BaseCamp’s proprietary LentiPeak™ lentiviral vector platform and clinical manufacturing to advance engineered TCR-T cell therapies targeting oncogenic driver mutations. Learn more: https://bit.ly/3YtPqGh.
-
-
ICYMI: We recently shared an update on ElevateBio’s new BaseCamp Pittsburgh biomanufacturing facility, built in collaboration with the University of Pittsburgh and the Richard King Mellon Foundation. Learn how this facility will drive the development and commercialization of transformative therapies. Read our latest Elevated Insight here: https://lnkd.in/dAvigdAQ.
-
-
Base editing is a method of gene editing that converts one nucleotide base into another without the need to cut both strands of DNA. Life Edit Therapeutics's PAM diversity enables base editing at more sites, allowing for the potential to make any edit anywhere in the genome and correct genetic mutations linked to diseases. #BaseEditing #PAMs
-
-
We offer our partners unmatched industry-leading expertise in product development. Our tools, resources and expertise ensure seamless transitions from concept to commercialization. We’re here to support you at any stage of your journey. Explore our end-to-end capabilities: https://lnkd.in/epnCHZu2.
-
-
Congratulations to the Abata Therapeutics team on this significant milestone! We are proud to be partnering on the advancement of ABA-101 for the treatment of people living with progressive multiple sclerosis.
The FDA Fast Track designation for ABA-101 for the treatment of progressive multiple sclerosis will enable us to expedite our efforts to bring ABA-101 to patients. This designation advances our mission, as initiation of a first-in-human (FIH) Phase 1 study is imminent. #clinicaltrials #drugdevelopment #MS https://bit.ly/4dWJrOZ
-
-
Designed to be readily accessible to patients, allogeneic cell therapy is an ‘off-the-shelf’ form of immunotherapy. Cells are taken from cell lines or health donors and engineered for on demand treatments. We’re leveraging our knowledge across gene editing and cell and vector engineering to optimize cells for this therapeutic approach. #AllogeneicCellTherapy #CellTherapy
-